Losartan Potassium: A Review of its Pharmacology, Clinical Efficacy and Tolerability in the Management of Hypertension

Drugs

Volumn 51, Issue 5, 1996, Pages 820-845

  Goa, Karen L ^a   Wagstaff, Antona J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; DRUG METABOLITE; ENALAPRIL; FELODIPINE; HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM; THIAZIDE DIURETIC AGENT;

ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; BORDERLINE HYPERTENSION; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; HYPERTENSION; HYPOTENSION; ORAL DRUG ADMINISTRATION; REVIEW; VERTIGO;

ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; HUMANS; HYPERTENSION; IMIDAZOLES; LOSARTAN; TETRAZOLES;

EID: 0029932496     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199651050-00008     Document Type: Review

References (138)

1. Smith RD, Sweet CS, Goldberg A, et al. Losartan potassium (Cozaar™): a nonpeptide antagonist of angiotensin II. Drugs Today 1995; 31 (7): 463-98
2. Timmermans PB, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993 Jun; 45: 205-51
3. Garrison JC, Peach MJ. Chapter 31. Renin and angiotensin. In: Gilman AG et al., editors. The pharmacological basis of therapeutics. New York: McGraw Hill Inc., 1992: 749-58
4. Cody RJ. The clinical potential of renin inhibitors and angiotensin antagonists. Drugs 1994 Apr; 47: 586-98
5. Timmermans PBMWM, Wong PC, Chiu AT, et al. The preclinical basis of the therapeutic evaluation of losartan. J Hypertens 1995; 13 Suppl. 1: S1-13
6. Chiu AT, Herblin WF, McCall DE, et al. Identification of angiotensin II receptor subtypes. Biochem Biophys Res Commun 1989; 165(1): 196-203
7. Tsutsumi K, Viswanathan M, Stromberg C, et al. Type-1 and type-2 angiotensin II receptors in fetal rat brain. Eur J Pharmacol 1991 May 30; 198: 89-92
8. Whitebread S, Mele M, Kamber B, et al. Preliminary biochemical characterization of two angiotensin II receptor subtypes. Biochem Biophys Res Commun 1989 Aug 30; 163: 284-91
9. Furuta H, Guo D-F, Inagami T. Molecular cloning and sequencing of the gene encoding human angiotensin II type 1 receptor. Biochem Biophys Res Commun 1992; 183 (1): 8-13
10. Iwai N, Inagami T. Identification of two subtypes in the rat type I angiotensin II receptor. FEBS Lett 1992 Feb; 298 (2,3): 257-60
11. Sasamura H, Hein L, Krieger JE, et al. Cloning, characterization, and expression of two angiotensin receptor (AT-1) isoforms from the mouse genome. Biochem Biophys Res Commun 1992 Feb; 185: 253-9
12. Timmermans PBMWM, Smith RD. Angiotensin II receptor subtypes: selective antagonists and functional correlates. Eur Heart J 1994 Dec; 15 Suppl. D: 79-87
13. 2 receptors, prostaglandins, kinins and nitric oxide. J Hypertens 1995; 13: 1779-84
14. Johnston CI. Angiotensin receptor antagonists: focus on losartan. Lancet 1995 Nov 5; 346: 1403-7
15. Chai SY, Zhuo J, Mendelsohn FA. Localization of components of the renin-angiotensin system and site of action of inhibitors. Arzneimittelforschung 1993 Feb; 43: 214-21
16. Chin AT, McCall DE, Ardecky RJ, et al. Angiotensin II receptor subtypes and their selective nonpeptide ligands. Receptor 1990-91 Winter; 1: 33-40
17. Regitz-Zagrosek V, Auch-Schelk W, Hess B, et al. Modulation of AngII receptors by chronic treatment with cyclosporin A, an ACE-inhibitor and AT1-blocker in rats [abstract no. 1055]. Eur Heart J 1996 Aug; 16 Abstract Suppl.: 182
18. Chiu AT, McCall DE, Price WA, et al. Nonpeptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DuP 735, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990 Feb; 252: 711-8
19. Sachinidis A, Ko Y, Weisser P, et al. EXP3174, a metabolite of losartan (MK 954, DuP 753) is more potent than losartan in blocking the angiotensin II-induced responses in vascular smooth muscle cells. J Hypertens 1993 Feb; 11: 155-62
20. Wong PC, Tam SW, Herblin WF, et al. Further studies on the selectivity of DuP 753, a nonpeptide angiotensin II receptor antagonist. Eur J Pharmacol 1991 Apr 17; 196: 201-3
21. Rhaleb N-E, Rouissi N, Nantel F, et al. DuP 753 is a specific antagonist for the angiotensin receptor. Hypertension 1991 Apr; 17: 480-4
22. 3H]DUP 753, a highly potent and specific radioligand for the angiotensin II-1 receptor subtype. Biochem Biophys Res Commun 1990 Nov 15; 172: 1195-202
23. Chiu AT, McCall DE, Price Jr WA, et al. In vitro pharmacology of DuP 753. Am J Hypertens 1991 Apr; 4 Suppl.: 282S-7S
24. Abdelrahman A, Pang CCY. Competitive antagonism of pressor responses to angiotensin II and angiotensin III by the angiotensin II-1 receptor ligand losartan. Can J Physiol Pharmacol 1992 May; 70: 716-9
25. Wong PC, Price WA, Chiu AT, et al. Nonpeptide angiotensin II receptor antagonists. VIII. Characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990 Feb; 252: 719-25
26. Wong PC, Price WA, Chiu AT, et al. Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990 Oct; 255: 211-7
27. Wong PC, Price WA, Chiu AT, et al. Nonpeptide angiotensin II receptor antagonists. IX. Antihypertensive activity in rats of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990 Feb; 252: 726-32
28. Cockcroft JR, Sciberras DG, Goldberg MR, et al. Comparison of angiotensin-converting enzyme inhibition with angiotensin II receptor antagonism in the human forearm. J Cardiovasc Pharmacol 1993 Oct; 22: 579-84
29. Goldberg MR, de Mey C, Wroblewski JM, et al. Differential eftects of oral losartan and enalapril on local venous and systemic pressor responses to angiotensin I and II in healthy men. Clin Pharmacol Ther 1996; 59 (1): 72-82
30. Christen Y, Waeber B, Nussberger J. Dose-response relationships following oral administration of DuP 753 to normal humans. Am J Hypertens 1991 Apr; 4 Suppl.: 350S-3S
31. Munafo A, Christen Y, Nussberger J, et al. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin Pharmacol Ther 1992 May; 51: 513-21
32. Burnier M, Rutschmann B, Nussberger J, et al. Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension 1993 Sep; 22: 339-47
33. Azizi M, Chatellier G, Thanh-Tam G, et al. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation 1995; 92: 825-34
34. Goldberg MR, Tanaka W, Barchowsky A, et al. Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers. Hypertension 1993 May; 21: 704-13
35. Doig JK, MacFadyen RJ, Sweet CS. Dose-ranging study of the angiotensin type 1 receptor antagonist losartan (DuP753/MK954), in salt-deplete normal man. J Cardiovasc Pharmacol 1993 May; 21: 732-8
36. Goldberg MR, Bradstreet TE, McWilliams EJ, et al. Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients. Hypertension 1995 Jan; 25: 37-46
37. Grossman E, Peleg E, Carroll J, et al. Hemodynamic and humoral effects of the angiotensin II antagonist losartan in essential hypertension. Am J Hypertens 1994 Dec; 7: 1041-4
38. Smith MC, Barrows S, Meibohm A, et al. The effects of angiotensin II receptor blockade with losartan on systemic blood pressure and renal and extrarenal prostaglandin synthesis in women with essential hypertension. Am J Hypertens 1995; 8: 1177-83
39. Opsahl JA, Goldberg MR, Katz SA. Effect of acute and chronic losartan therapy on active and inactive renin and active renin glycoforms. Am J Hypertens 1995; 8: 1090-8
40. Wong PC, Price JWA, Chiu AT, et al. Hypotensive action of DuP 753, an angiotensin II antagonist, in spontaneously hypertensive rats: nonpeptide angiotensin II receptor antagonists: X. Hypertension 1990 May; 15: 459-68
41. Gradman AH, Arcuri KE, Goldberg AI, et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995 Jun; 25: 1345-50
42. Arcuri K, Harm S, Nelson E, et al. Efficacy and safety of concomitant losartan (L) hydrochlorothiazide (H) therapy in patients with essential hypertension [abstract no. 148]. Am J Hypertens 1994; 7 (4 Pt 2): 110A
43. Meredith PA. Trough/peak ratios of antihypertensive agents. Drugs 1994 Nov; 48 (5): 661-6
44. Weber MA, Byyny RL, Pratt JH, et al. Blood pressure effects of the angiotensin II receptor blocker, losartan. Arch Intern Med 1995 Feb 27; 155: 405-11
45. Stapff M, Dueck KD, Richard F, et al. Evaluation of the antihypertensive efficacy of losartan, an angiotensin II antagonist, compared to captopril using 24h ABPM [abstract no. 806]. Seventh European Meeting on Hypertension, 1995: 183.
46. Goldberg MR, Staub T, Ermlich S, et al. First-dose effects of losartan vs captopril in thiazide-treated hypertensive patients [abstract]. Clin Pharmacol Ther In press
47. Otsuka K, Tsukiyama H. Hemodynamic effects of MK-954 (losartan potassium), an angiotensin II receptor antagonist, in patients with essential hypertension [in Japanese]. Rinsho Iyaku 1995; 11 (1): 165-74
48. Cody RJ, Hunnicutt M, Sinnathamby S, et al. The long term systemic and ventricular hemodynamic response to losartan is comparable to enalapril, in pressure overload ventricular dysfunction [abstract]. Clin Res 1994 Oct; 42: 351A
49. 1-receptor antagonist losartan on arterial compliance in hypertensives [abstract]. J Hypertens 1994 Mar; 12 Suppl. 3: S91
50. Himmelmann A, Svensson A, Dahlöf B, et al. Atenolol versus losartan in hypertension - focus on left ventricular morphology [abstract]. J Hypertens 1994 Mar; 12 Suppl. 3: S98
51. 1 receptor antagonist, and surgical reversal. J Cardiovasc Pharmacol 1994 Feb; 23: 291-9
52. Mizuno K, Tani M, Hashimoto S, et al. Effects of losartan, a nonpeptide angiotensin-II receptor antagonist, on cardiac hypertrophy and the tissue angiotensin II content in spontaneously hypertensive rats. Life Sci 1992; 51 (5): 367-74
53. Nishimura N, Takase H, Morita T. Comparative effects of chronic treatment with losartan or captopril on myocardial and vascular hypertrophy in SHRs [abstract]. Jpn J Pharmacol 1994; 64 Suppl. 1: 330P
54. 1 receptor. Am J Hypertens 1992 May; 5 (5 Pt 1): 276-80
55. Ruzicka M, Yuan B, Leenen FHH. Effects of enalapril versus losartan on regression of volume overload-induced cardiac hypertrophy in rats. Circulation 1994 Jul; 90: 484-91
56. 1 receptor antagonism on left ventricular hypertrophy in rats [abstract no. 503]. J Hypertens 1994; 12 Suppl. 3: S91
57. Hunnicutt M, Alton ME, Haas GJ, et al. Attenuated development of left ventricular hypertrophy (LVH) with long term DUP753 in the spontaneously hypertensive rat [abstract no. 1122.]. Am J Hypertens 1993 May; 6 (5 Pt 2): 28A
58. Ishiye M, Umemura K, Uematsu T, et al. Effect of losartan, an angiotensin II receptor antagonist, on volume overload cardiac hypertrophy [abstract no. 0-130]. Jpn J Pharmacol 1992; 58 Suppl. 1: 100P
59. 1 angiotensin II inhibition. J Hypertens 1995; 13: 1808-12
60. Broten TP, Gibson RE, Cartwright ME, et al. Losartan and enalapril prevent cardiac hypertrophy and intramural coronary arterial hypertrophy and fibrosis in a low renin model of hypertension [abstract]. FASEB J 1994 Mar 15; 8 (Pt 1): 310
61. Wilm C, Lues I, Schelling P. Regression of vascular hypertrophy in renal hypertensive rats treated with the angiotensin II antagonist losartan [abstract]. J Hypertens 1994 Mar; 12 Suppl 3: S90
62. Ling Q, Guo Z-G, Su Z, et al. Regression of cardiac hypertrophy and myosin isoenzyme patterns by losartan and captopril in renovascular hypertensive rats. Acta Pharmacol Sin 1994 May; 15 (3): 206-10
63. Nicoletti A, Heudes D, Hinglais N, et al. Left ventricular fibrosis in renovascular hypertensive rats. Hypertension 1995; 26: 101-11
64. Fornes P, Richer C, Vacher E, et al. Losartan's protective effects in stroke-prone spontaneously hypertensive rats persist durably after treatment withdrawal. J Cardiovasc Pharmacol 1993 Aug; 22: 305-13
65. Stier Jr CT, Adler LA, Levine S, et al. Stroke prevention by losartan in stroke-prone spontaneously hypertensive rats. J Hypertens 1993 Apr: 11 Suppl. 3: S37-42
66. Camargo MJ, von Lutterolti N, Campbell Jr WG, et al. Control of blood pressure and end-organ damage in maturing salt-loaded stroke-prone spontaneously hypertensive rats by oral angiotensin II receptor blockade. J Hypertens 1993 Jan; 11: 31-40
67. von Lutterotti N, Camargo MJ, Campbell Jr WG, et al. Angiotensin II receptor antagonist delays renal damage and stroke in salt-loaded Dahl salt-sensitive rats. J Hypertens 1992 Sep; 10: 949-57
68. Medina R, Cardona-Sanclemente LE, Born GVR. Effect of angiotensin II and losartan on the incorporation of human and rat low-density lipoprotein by organs of normotensive and hypertensive rats [abstract no. 1591]. Eur Heart J 1995 Aug; 16 (6): 274
69. Chabielska E, Pawlak R, Golatowski J, et al. Influence of losartan on platelet aggregation and venous thrombosis in rats [abstract no. 1658]. Thromb Haemost 1995 June; 73 (6): 1332
70. Tsunoda K, Abe K, Hagino T, et al. Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension. Am J Hypertens 1993 Jan; 6: 28-32
71. Fauvel JP, Laville M, Maakel N, et al. Effects of losartan on renal hemodynamic parameters in hypertensives [abstract]. J Hypertens 1994 Mar; 12 Suppl. 3: S93
72. Erley CM, Bader B, Scheu M, et al. Renal hemodynamics in essential hypertensives treated with losartan. Clin Nephrol 1995 Jan; 43 Suppl. 1: S8-11
73. Chan JCN, Critchley JAJH, Tomlinson B, et al. Antihypertensive and anti-albuminuric effects of losartan potassium and felodipine-ER in Chinese elderly hypertensive patients with or without NIDDM. Am J Nephrol In press
74. Nakashima M, Uematsu T, Kosuge K. Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 1992 Mar; 42: 333-5
75. Shaw W, Keane W, Sica D, et al. Safety and antihypertensive effects of losarlan (MK-954; DUP753) a new angiotensin II receptor antagonist, in patients with hypertension and renal disease [abstract]. Clin Pharmacol Ther 1993 Feb; 53: 140
76. Gansevoort RT, de Zeeuw D, Shahinfar S, et al. Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease. J Hypertens 1994 Jul; 12 Suppl. 2: S37-42
77. Campbell DJ, Kladis A, Valentijn AJ. Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme. J Cardiovasc Pharmacol 1995; 26 (2): 233-40
78. Moan A, Hoieggen A, Eide I. Metabolic effects of antihypertensive treatment with the angiotensin II receptor antagonist losartan [abstract no. 551]. Seventh European Meeting on Hypertension, 1995.
79. Sami H, Laurel C, Anderson PW. Effects of losartan treatment in hypertensive patients [abstract]. J Invest Med 1995 Feb; 43 Suppl. 1: 199A
80. de Zeeuw D, Gansevoort RT, Dullaart RPF, et al. Angiotensin II antagonism improves the lipoprotein profile in patients with nephrotic syndrome. J Hypertens 1995; 13 Suppl. 1: S53-8
81. Moan A, Risanger T, Eide I. The effect of angiotensin II receptor blockade on insulin sensitivity and sympathetic nervous system activity in primary hypertension. Blood Press 1994 May; 3: 185-8
82. 2 release in human saphenons vein stimulated by angiotensin II [abstract no. 198P]. Br J Pharmacol 1995 Oct: 116
83. Sasaski M, Fujimura A, Harada K, et al. Effect of losartan, an angiotensin II receptor antagonist, on response of cortisol and aldosterone to adrenocorticotrophic hormone. J Clin Pharmacol 1995 Aug; 35: 776-9
84. Stearns RA, Miller RR, Doss GA, et al. The metabolism of DuP 753, a nonpeptide angiotensin II receptor antagonist, by rat, monkey, and human liver slices. Drug Metab Dispos 1992 Mar-Apr; 20: 281-7
85. Funtek CI, Lo M-W. Simultaneous determination of a novel angiotensin II receptor blocking agent, losartan, and its metabolite in human plasma and urine by high-performance liquid chromatography. J Chromatogr 1992 Jan 17; 573: 295-301
86. Lo M-W, Goldberg MR, McCrea JB, et al. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 1995 Dec; 58: 641-9
87. Ohtawa M, Takayama F, Saitoh K. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans. Br J Clin Pharmacol 1993 Mar; 35: 290-7
88. Merck & Co., Inc. Losartan potassium prescribing information. West Point, PA 19486, USA, April, 1995.
89. Christ DD. Human plasma protein binding of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) and its pharmacologically active metabolite EXP3174. J Clin Pharmacol 1995 May; 35: 515-30
90. Li ZH, Bains JS, Ferguson AV. Functional evidence that the angiotensin antagonist losartan crosses the blood-brain barrier in the rat. Brain Res Bull 1993; 30 (1-2): 33-9
91. Soldner A, Spahn-Langguth H, Mutschler E. Disposition profiles of losartan and EXP 3174 in rat tissues and body fluids following single and multiple oral dosing [abstract no. 790]. Seventh European Meeting on Hypertension, 1995.
92. Bui JD, Kimura B, Phillips MI. Losartan potassium, a nonpeptide antagonist of angiotensin II, chronically administered p.o. does not readily cross the blood-brain barrier. Eur J Pharmacol 1992 Aug 14; 219: 147-51
93. Stevenson KM, Gibson KJ, Lumbers ER, et al. Comparison of the transplacental transfer of enalapril, captopril and losartan in sheep. Br J Pharmacol 1995 Apr; 114: 1495-501
94. Sica DA, Lo M-W, Shaw WC, et al. The pharmacokinetics of losartan in renal insufficiency. J Hypertens 1995; 13 Suppl. 1: S49-52
95. Stearns RA, Chakravarty PK, Chen R, et al. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes: role of cytochrome P4502C and 3A subfamily members. Drug Metab Dispos 1995 Feb; 23: 207-15
96. Yun C-H, Lee HS, Lee H, et al. Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes: role of cytochrome P4503A(4) in formation of the active metabolite EXP3174. Drug Metab Dispos 1995 Feb; 23: 285-9
97. 1-selective non-peptide angiotensin II receptor antagonist. Eur J Clin Pharmacol 1995; 49: 115-9
98. McCrea JB, Lo M-W, Furtek CI, et al. Ketoconazole does not affect the systemic conversion of losartan to E-3174 [abstract]. Clin Pharmacol Ther In press
99. Goldberg MR, Lo M-W, Deutsch PJ, et al. Phenobarbital minimally afters plasma concentrations of losartan and its active metabolite E-3174. Clin Pharmacol Ther In press; 59
100. Spielberg S, McCrea J, Cribb A, et al. A mutation in CYP2C9 is responsible for decreased metabolism of losartan [abstract]. Clin Pharmacol Ther In press
101. McCrea J, Lo M-W, Kong T, et al. A rare deficiency of the conversion of losartan to its active metabolite, E3174 [abstract]. Clin Pharmacol Ther In press
102. Kong A-NT, Tomasko L, Waldman SA, et al. Losartan does not affect the pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol 1995; 35: 1008-15
103. De Smet M, Schoors DF, De Meyer G, et al. Effect of multiple doses of losartan on the pharmacokinetics of single doses of digoxin in healthy volunteers. Br J Clin Pharmacol 1995 Dec; 40: 571-5
104. McCrea JB, Lo M-W, Tomasko L, et al. Absence of a pharmacokinetic interaction between losartan and hydrochlorothiazide. J Clin Pharmacol 1995; 35: 1200-6
105. Nelson E, Merrill D, Sweet C, et al. Efficacy and safety of oral MK-954 (DuP 753), an angiotensin antagonist, in essential hypertension [abstract]. J Hypertens 1991 Dec; 9 Suppl. 6: S468
106. Tikkanen I, Omvik P, Jensen HÆ et al. Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. Hypertension 1995; 13: 1343-51
107. Mallion J-M, Bradstreet DC, Makris L. et al. Antihypertensive efficacy and tolerability of once daily losartan potassium compared with captopril in patients with mild to moderate essential hypertension. J Hypertens 1995; 13 Suppl. 1: S35-41
108. Dahlöf B, Keller SE, Makris L, et al. Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension. Am J Hypertens 1995 Jun; 8: 578-83
109. Chan JCN, Critchley JAJH, Lappe JT, et al. Randomised, double-blind, parallel study of the anti-hypertensive efficacy and safety of losartan potassium compared with felodipine ER in elderly patients with mild to moderate hypertension. J Hum Hypertens 1995; 9: 765-71
110. Dunlay MC, Fitzpatrick V, Chrysant S, et al. Losartan potassium as initial therapy in patients with severe hypertension. J Hum Hypertens 1995; 9: 861-7
111. Velivis M, Dai XC, Goldberg AI, et al. Safety and efficacy of losartan potassium/hydrochlorothiazide combination tablet in patients with severe hypertension [abstract]. Am J Hypertens 1995 Apr; 8 Pt 2: 192A
112. Simpson RL, Morlin C, Toh J, et al. Efficacy and safety of losartan combined with hydrochlorothiazide in patients with mild to severe hypertension [abstract]. Am J Hypertens 1994 Apr; 7 (Pt 2): 37A
113. MacKay JH, Arcuri KE, Goldberg AI, et al. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. Arch Intern Med 199; 156: 278-85
114. Soffer BA, Wright Jr JT, Pratt JH, et al. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 1995 July; 26 (1): 112-7
115. Townsend R, Haggert B, Liss C, et al. Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension. Clin Ther 1995; 17 (5): 911-23
116. Gazdick LP, Maxwell M, Ruff D, et al. A double-blind, randomized, parallel, active-controlled study to evaluate the antihypertensive efficacy and safety of losartan in patients with severe hypertension [abstract]. Am J Hypertens 1994 Apr; 7 (Pt 2): 100A
117. Schoenberger JA. The Losartan Research Group. Losartan with hydrochlorothiazide in the treatment of hypertension. J Hypertens 1995; 13 Suppl. 1: S43-7
118. de Zeeuw D, Gansevoort RT, de Jong PE. Losartan in patients with renal insufficiency. Can J Cardiol 1995; 11 Suppl. F: 41F-4F
119. Yoshinaga K, Abe K, Iimura O, et al. Efficacy, safely and usefulness of MK-954 (losartan potassium), angiotensin II receptor antagonist, on essential hypertension in the long-term treatment [in Japanese]. Rinsho Iyaku 1995; 11 (1): 175-207
120. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 1995 Apr 15; 75: 793-5
121. Ahmad S. Losartan and severe migraine [letter]. JAMA 1995 Oct 25; 274 (16): 1266-7
122. Schlienger RG, Saxer M, Haefeli WE. Reversible ageusia associated with losartan [letter]. Lancet 1996 Feb 17; 347: 471-2
123. Acker CG, Greenberg A. Angioedema induced by the angiotensin II blocker losartan [letter]. N Engl J Med 1995 Dec 7; 333: 1572
124. Shand BI, Gilchrist NL, Nicholls MG, et al. Effect of losartan on haematology and haemorheology in elderly patients with essential hypertension: a pilot study. J Hum Hypertens 1995 Apr; 9: 233-5
125. Karlberg BE. Cough and inhibition of the renin-angiotensin system. J Hypertens Suppl 1993 Apr; 11: S49-52
126. Lacourcière Y, Lefebvre J. Modulation of the renin-angiotensin-aldosterone system and cough. Can J Cardiol 1995; 11 Suppl. F: 33F-9F
127. Fletcher AE, Palmer AJ, Bulpitt CJ. Cough with angiotensin converting enzyme inhibitors: how much of a problem? J Hypertens 1994; 12 Suppl. 2: S43-7
128. Lacourcière Y, Brunner H, Irwin R, et al. Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertens 1994 Dec; 12: 1387-93
129. Anon. Merck Cozaar cough advantage over ACE inhibitors labeling claim. FDC Rep Pink Sheet 1996 Jan 8
130. Merck & Co., Inc. Losartan potassium-hydrochlorothiazide prescribing information. West Point, PA, USA. April, 1995.
131. Wexler RR, Carini DJ, Duncia JV, et al. Rationale for the chemical development of angiotensin II receptor antagonists. Am J Hypertens 1992 Dec; 5 Suppl.: 209S-20S
132. Pitt B, Chang P, Timmermans PBMWWM. Angiotensin II receptor antagonists in heart failure: rationale and design of the Evaluation of Losartan in the Elderly (ELITE) trial. Cardiovasc Drugs Ther 1995;: 9: 693-700
133. Sever P, Beevers G, Bulpitt C, et al. Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society. BMJ 1993 April 10; 306: 983-7
134. Joint National Committee on Detection Evaluation and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993; 153: 154-83
135. Weber MA. Controversies in the diagnosis and treatment of hypertension: a personal review of JNC V. Am J Cardiol 1993; 72: 3H-9H
136. Elliott WJ. Controversies regarding the recommendations of the Fifth Report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. Comprehensive Therapy 1994; 20 (3): 181-5
137. Edelman JM, Gazdick LP, Epstein RS, et al. Trial of Usual Care for Hypertension (TOUCH): an effectiveness study of newly treated hypertension comparing losartan potassium and usual care in a managed care setting. Am J Hypertens 1995 Apr; 8(Pt 2): 79
138. Shaw W, Snavely D. Safety and efficacy of losartan (DuP 753, MK 954) in hypertensive patients with renal impairment [abstract]. J Am Soc Nephrol 1994; 5: 567